Need urgent consulting? Call 1-208-971-6430

Pharmaceutical FDA Inspections and Compliance Support

Navigate FDA Pharmaceutical Inspections With Confidence and Expertise

Image of Pharmaceutical FDA Inspections


At FDAInspections.com, we help long-term, established and start-up pharmaceutical manufacturers, contract manufacturers (CMOs), and packagers prepare for and succeed during FDA inspections. Whether you’re facing a Pre-Approval Inspection (PAI), a routine cGMP inspection, or a for-cause audit, our team of experts provides the strategic guidance and hands-on support you need to stay compliant and inspection-ready.

Our mission: Empower pharmaceutical companies to pass FDA inspections, resolve FDA-483s and Warning Letters, and build defensible quality systems that withstand regulatory scrutiny.

Types of Pharmaceutical Products We Support

At FDAInspections.com, we help pharmaceutical companies, contract manufacturers (CMOs), packagers, and distributors across a broad range of drug product types, including:

Prescription Drug Products (Rx)

  • Tablets, capsules, oral suspensions

  • Injectable drugs (vials, prefilled syringes, IV solutions)

  • Topical creams, ointments, gels

Support includes:

  • cGMP readiness audits for 21 CFR Part 210/211 compliance

  • Batch record review and deviation management

  • 483 response and Warning Letter remediation for drug manufacturing issues


Over-the-Counter (OTC) Drug Products

  • Analgesics (pain relievers), cough and cold products

  • Antiseptics, first aid creams, sunscreen products

  • Anti-dandruff shampoos, fluoride toothpaste

Support includes:

  • Label compliance under FDA Monographs and OTC labeling rules

  • cGMP compliance checks for OTC manufacturing sites

  • Recall readiness and complaint handling system reviews


Sterile Products

  • Injectable solutions

  • Ophthalmic (eye) products

  • Inhalation therapies

Support includes:

  • Aseptic processing validation audits

  • Environmental monitoring program evaluations

  • Sterility assurance and cleanroom operations readiness


Biologic Products (Traditional Biologics)

  • Vaccines, allergenics, blood products

  • Cell-based therapies (traditional CBER products)

Support includes:

  • Biologics License Application (BLA) inspection preparation

  • Cross-functional regulatory pathway support (21 CFR Part 600–680)

  • Facility and quality system inspection readiness


Active Pharmaceutical Ingredients (APIs) and Excipients

  • Raw material manufacturers and distributors

  • Contract API manufacturers

Support includes:

  • API cGMP inspections (ICH Q7 compliance)

  • Supplier qualification programs

  • Data integrity and laboratory control audits


Why FDA Pharmaceutical Inspections Matter

Pharmaceutical inspections are governed by strict FDA regulations under:

  • 21 CFR Part 210 – Current Good Manufacturing Practice (cGMP) for Manufacturing, Processing, Packing, or Holding of Drugs

  • 21 CFR Part 211 – cGMP for Finished Pharmaceuticals

  • 21 CFR Part 600 – Biological Products: General

Failure to comply can result in:

  • Form FDA 483 Observations

  • Warning Letters

  • Import Alerts

  • Consent Decrees

  • Product seizures or recalls

Preparation, documentation, and culture of quality are non-negotiable in today’s regulatory environment.

🔗 Learn about cGMP Regulations for Pharmaceuticals (FDA.gov)


How FDA Inspections .com Helps Pharmaceutical Companies

1. FDA Inspection Readiness Audits

We perform in-depth mock inspections modeled after FDA procedures to uncover vulnerabilities before real inspectors do.

  • Comprehensive cGMP system audits

  • SOP, batch record, and deviation review

  • Facility walkthroughs and data integrity checks

  • Interview preparation for QA, QC, Production, and Regulatory Affairs teams

Schedule an FDA Readiness Audit


2. FDA-483 Response and Warning Letter Remediation

If you’ve received a FDA_483 or Warning Letter, FDAInspections.com provides urgent and effective remediation support.

  • Root cause analysis

  • Corrective and Preventive Action (CAPA) plan development

  • Professional FDA-483 responses that meet FDA expectations

  • Mock re-inspections to ensure readiness for FDA follow-up

Get Help With Your 483 Response


3. Pre-Approval Inspection (PAI) Preparation

Launching a new drug product? We help you prepare for your critical Pre-Approval Inspection.

  • NDA, ANDA, or BLA inspection readiness

  • Validation program reviews (process, cleaning, analytical)

  • Site Master File (SMF) and quality system readiness evaluations

Prepare for Your PAI Inspection


4. Data Integrity and Electronic Records Compliance

We assess and strengthen compliance with 21 CFR Part 11 for electronic records and data integrity.

  • Data lifecycle reviews

  • Audit trail evaluations

  • Risk-based gap assessments and remediation planning

Learn More About Data Integrity Support


Common Areas of FDA Pharmaceutical Inspection Focus

  • Batch production and control records

  • Laboratory controls and Out-of-Specification (OOS) procedures

  • Change control processes

  • Cleaning validation

  • Equipment qualification (IQ, OQ, PQ)

  • Annual Product Reviews (APR)

  • Supplier qualification and management

  • Personnel training and qualification


Frequently Asked Questions About Pharmaceutical FDA Inspections

Q: What triggers an FDA pharmaceutical inspection?
A: Inspections may be routine (biennial surveillance), for a new product approval (PAI), or for-cause based on complaints, recalls, or previous compliance issues.


Q: What is the difference between a PAI and a surveillance inspection?
A: A Pre-Approval Inspection (PAI) evaluates readiness to market a new product under an NDA or ANDA, while surveillance inspections evaluate ongoing cGMP compliance at established facilities.


Q: How long does it take to prepare for an FDA inspection?
A: Ideally, inspection readiness is an ongoing state. However, a focused preparation project typically takes 4–12 weeks depending on gaps identified.


Q: Can FDAInspections.com help even after a 483 or Warning Letter?
A: Absolutely. We specialize in rapid response, CAPA development, and helping companies successfully navigate follow-up inspections and demonstrate sustainable corrections.


Q: Do you offer remote (virtual) inspection readiness support?
A: Yes. We offer both remote document reviews, virtual mock inspections, and in-person site assessments depending on client needs.


 


FDAInspections.com — Your Trusted Partner for Pharmaceutical FDA Compliance and Inspection Success.

Scroll to Top